Lee's Pharmaceutical Holdings Limited (0950.HK)
HKD 1.22
(-3.17%)
HKD 1.22
(-3.17%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 551.31 Million HKD | -28.47% |
| 2022 | 770.75 Million HKD | -4.41% |
| 2021 | 806.28 Million HKD | 3.23% |
| 2020 | 781.06 Million HKD | -2.15% |
| 2019 | 798.25 Million HKD | 6.95% |
| 2018 | 746.37 Million HKD | 9.37% |
| 2017 | 682.4 Million HKD | 2.12% |
| 2016 | 668.23 Million HKD | 3.1% |
| 2015 | 648.16 Million HKD | -3.33% |
| 2014 | 670.52 Million HKD | 33.24% |
| 2013 | 503.25 Million HKD | 32.14% |
| 2012 | 380.83 Million HKD | 30.5% |
| 2011 | 291.83 Million HKD | 63.5% |
| 2010 | 178.49 Million HKD | 43.28% |
| 2009 | 124.57 Million HKD | 40.54% |
| 2008 | 88.64 Million HKD | 73.83% |
| 2007 | 50.99 Million HKD | 91.19% |
| 2006 | 26.67 Million HKD | 5.37% |
| 2005 | 25.31 Million HKD | 26.47% |
| 2004 | 20.01 Million HKD | 49.76% |
| 2003 | 13.36 Million HKD | 58.27% |
| 2002 | 8.44 Million HKD | 7.16% |
| 2001 | 7.88 Million HKD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 Q4 | 133.42 Million HKD | 0.0% |
| 2023 Q2 | 142.23 Million HKD | 0.0% |
| 2023 Q1 | 142.23 Million HKD | 30.54% |
| 2023 FY | 551.31 Million HKD | -28.47% |
| 2023 Q3 | 133.42 Million HKD | -6.19% |
| 2022 Q4 | 108.95 Million HKD | -55.04% |
| 2022 Q1 | 215.82 Million HKD | 25.85% |
| 2022 Q2 | 203.65 Million HKD | -5.64% |
| 2022 Q3 | 242.32 Million HKD | 18.99% |
| 2022 FY | 770.75 Million HKD | -4.41% |
| 2021 Q2 | 194.13 Million HKD | 0.9% |
| 2021 Q4 | 171.48 Million HKD | -30.92% |
| 2021 FY | 806.28 Million HKD | 3.23% |
| 2021 Q3 | 248.25 Million HKD | 27.87% |
| 2021 Q1 | 192.41 Million HKD | -6.32% |
| 2020 FY | 781.06 Million HKD | -2.15% |
| 2020 Q1 | 180.51 Million HKD | -8.53% |
| 2020 Q2 | 185.1 Million HKD | 2.54% |
| 2020 Q3 | 210.05 Million HKD | 13.48% |
| 2020 Q4 | 205.39 Million HKD | -2.22% |
| 2019 FY | 798.25 Million HKD | 6.95% |
| 2019 Q3 | 198.58 Million HKD | -6.91% |
| 2019 Q4 | 197.34 Million HKD | -0.62% |
| 2019 Q1 | 188.99 Million HKD | 8.82% |
| 2019 Q2 | 213.33 Million HKD | 12.87% |
| 2018 Q4 | 173.68 Million HKD | -10.68% |
| 2018 Q2 | 185.67 Million HKD | -3.57% |
| 2018 Q1 | 192.55 Million HKD | 7.77% |
| 2018 FY | 746.37 Million HKD | 9.37% |
| 2018 Q3 | 194.45 Million HKD | 4.73% |
| 2017 Q2 | 169.48 Million HKD | 13.39% |
| 2017 Q1 | 149.47 Million HKD | -12.59% |
| 2017 FY | 682.4 Million HKD | 2.12% |
| 2017 Q3 | 184.77 Million HKD | 9.02% |
| 2017 Q4 | 178.67 Million HKD | -3.3% |
| 2016 Q4 | 171 Million HKD | 0.9% |
| 2016 Q3 | 169.48 Million HKD | 0.08% |
| 2016 Q1 | 158.41 Million HKD | 6.69% |
| 2016 Q2 | 169.34 Million HKD | 6.9% |
| 2016 FY | 668.23 Million HKD | 3.1% |
| 2015 FY | 648.16 Million HKD | -3.33% |
| 2015 Q3 | 161.86 Million HKD | -7.09% |
| 2015 Q2 | 174.21 Million HKD | 6.48% |
| 2015 Q1 | 163.61 Million HKD | -13.09% |
| 2015 Q4 | 148.47 Million HKD | -8.27% |
| 2014 Q2 | 163.85 Million HKD | 11.0% |
| 2014 Q3 | 170.8 Million HKD | 4.24% |
| 2014 Q4 | 188.24 Million HKD | 10.21% |
| 2014 FY | 670.52 Million HKD | 33.24% |
| 2014 Q1 | 147.61 Million HKD | 8.53% |
| 2013 Q2 | 131.39 Million HKD | 23.0% |
| 2013 Q3 | 129.01 Million HKD | -1.82% |
| 2013 Q4 | 136.01 Million HKD | 5.43% |
| 2013 FY | 503.25 Million HKD | 32.14% |
| 2013 Q1 | 106.82 Million HKD | 2.6% |
| 2012 FY | 380.83 Million HKD | 30.5% |
| 2012 Q3 | 94.74 Million HKD | -8.82% |
| 2012 Q1 | 78.06 Million HKD | -13.88% |
| 2012 Q2 | 103.9 Million HKD | 33.1% |
| 2012 Q4 | 104.12 Million HKD | 9.9% |
| 2011 Q1 | 54.32 Million HKD | 0.0% |
| 2011 Q4 | 90.64 Million HKD | 14.27% |
| 2011 FY | 291.83 Million HKD | 63.5% |
| 2011 Q2 | 67.53 Million HKD | 24.32% |
| 2011 Q3 | 79.32 Million HKD | 17.46% |
| 2010 FY | 178.49 Million HKD | 43.28% |
| 2010 Q2 | 42.86 Million HKD | 0.0% |
| 2009 Q2 | 31.84 Million HKD | 0.0% |
| 2009 FY | 124.57 Million HKD | 40.54% |
| 2008 FY | 88.64 Million HKD | 73.83% |
| 2007 FY | 50.99 Million HKD | 91.19% |
| 2006 FY | 26.67 Million HKD | 5.37% |
| 2005 FY | 25.31 Million HKD | 26.47% |
| 2004 FY | 20.01 Million HKD | 49.76% |
| 2003 FY | 13.36 Million HKD | 58.27% |
| 2002 FY | 8.44 Million HKD | 7.16% |
| 2001 FY | 7.88 Million HKD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 167.43 Million HKD | -229.267% |
| Grand Pharmaceutical Group Limited | 6.52 Billion HKD | 91.55% |
| Extrawell Pharmaceutical Holdings Limited | 28.77 Million HKD | -1815.671% |
| Wai Yuen Tong Medicine Holdings Limited | 394.81 Million HKD | -39.639% |
| Qianhai Health Holdings Limited | -35.6 Million HKD | 1648.496% |
| Essex Bio-Technology Limited | 1.53 Billion HKD | 64.184% |
| Tongfang Kontafarma Holdings Limited | 471.29 Million HKD | -16.979% |
| PuraPharm Corporation Limited | 216.62 Million HKD | -154.495% |
| SSY Group Limited | 3.48 Billion HKD | 84.199% |
| JBM (Healthcare) Limited | 319.41 Million HKD | -72.6% |
| Jacobson Pharma Corporation Limited | 620.47 Million HKD | 11.147% |
| China Resources Pharmaceutical Group Limited | 43.36 Billion HKD | 98.729% |